Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1968 1
1980 1
1982 1
1983 1
1985 1
1990 2
1993 2
1994 2
1995 2
1996 7
1997 4
1998 4
1999 6
2000 5
2001 8
2002 7
2003 4
2004 8
2005 10
2006 6
2007 6
2008 6
2009 5
2010 6
2011 6
2012 4
2013 4
2014 17
2015 19
2016 19
2017 9
2018 16
2019 9
2020 16
2021 16
2022 13
2023 13
2024 19
2025 19
2026 19

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

288 results

Results by year

Filters applied: . Clear all
Page 1
The 2021 European Group on Graves' orbitopathy (EUGOGO) clinical practice guidelines for the medical management of Graves' orbitopathy.
Bartalena L, Kahaly GJ, Baldeschi L, Dayan CM, Eckstein A, Marcocci C, Marinò M, Vaidya B, Wiersinga WM; EUGOGO †. Bartalena L, et al. Eur J Endocrinol. 2021 Aug 27;185(4):G43-G67. doi: 10.1530/EJE-21-0479. Eur J Endocrinol. 2021. PMID: 34297684 Free article.
Risk factors include smoking, thyroid dysfunction, high serum level of thyrotropin receptor antibodies, radioactive iodine (RAI) treatment, and hypercholesterolemia. ...A cumulative dose of 4.5 g of i.v. methylprednisolone in 12 weekly infusions is the optima …
Risk factors include smoking, thyroid dysfunction, high serum level of thyrotropin receptor antibodies, radioactive iodine (RA …
Fibroblast Activation Protein-Targeted Radioligand Therapy with 177Lu-EB-FAPI for Metastatic Radioiodine-Refractory Thyroid Cancer: First-in-Human, Dose-Escalation Study.
Fu H, Huang J, Zhao T, Wang H, Chen Y, Xu W, Pang Y, Guo W, Sun L, Wu H, Xu P, Su B, Zhang J, Chen X, Chen H. Fu H, et al. Clin Cancer Res. 2023 Dec 1;29(23):4740-4750. doi: 10.1158/1078-0432.CCR-23-1983. Clin Cancer Res. 2023. PMID: 37801296 Free PMC article. Clinical Trial.
Two patients experienced grade 3 and 4 hematotoxicity in Group C (4.99 GBq/cycle). The mean whole-body effective dose was 0.17 0.04 mSv/MBq. Intense 177Lu-LNC1004 uptake and prolonged tumor retention resulted in high mean absorbed tumor doses (8.50 12.36 Gy/GBq) …
Two patients experienced grade 3 and 4 hematotoxicity in Group C (4.99 GBq/cycle). The mean whole-body effective dose was 0.17 0.04 …
Vesicoureteral Reflux.
Leslie SW, Aeddula NR. Leslie SW, et al. 2024 Apr 30. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2026 Jan–. 2024 Apr 30. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2026 Jan–. PMID: 33085409 Free Books & Documents.
Grades III to V are considered dilating or high-grade VUR and are associated with an increased risk of UTIs and renal scarring, especially grades IV and V. ...Several studies have demonstrated the effectiveness and safety of intermittent intravesical antimicrobial t …
Grades III to V are considered dilating or high-grade VUR and are associated with an increased risk of UTIs and renal scarring, espec …
Low-Dose Versus High-Dose Lenvatinib in Radioiodine Refractory Differentiated Thyroid Cancer-A Real-World Safety and Efficacy Analysis.
Moulika JS, Chandekar KR, Ravindra SG, G B P, Ballal S, Tripathi M, Satapathy S, Bal C. Moulika JS, et al. Clin Endocrinol (Oxf). 2025 Jun;102(6):721-729. doi: 10.1111/cen.15214. Epub 2025 Feb 4. Clin Endocrinol (Oxf). 2025. PMID: 39901765
OBJECTIVE: Lenvatinib, a tyrosine kinase inhibitor, is approved for the treatment of radioiodine refractory differentiated thyroid cancer (RR-DTC) at a dose of 24 mg/day. Given its significant toxicity profile, the present study aimed to compare the safety and effic …
OBJECTIVE: Lenvatinib, a tyrosine kinase inhibitor, is approved for the treatment of radioiodine refractory differentiated thyroid cancer (R …
The Nonpeptide Agonist MK-5046 Functions As an Allosteric Agonist for the Bombesin Receptor Subtype-3.
Ramos-Alvarez I, Iordanskaia T, Mantey SA, Jensen RT. Ramos-Alvarez I, et al. J Pharmacol Exp Ther. 2022 Aug;382(2):66-78. doi: 10.1124/jpet.121.001033. Epub 2022 May 29. J Pharmacol Exp Ther. 2022. PMID: 35644465 Free PMC article.
Furthermore, MK-5046 shows other allosteric behaviors, including slowing dissociation of the BRS-3 receptor ligand (125)I-Bantag-1, dose-inhibition curves being markedly affected by increasing ligand concentration, and MK-5046 leftward shifting the peptide-1 agonist dos …
Furthermore, MK-5046 shows other allosteric behaviors, including slowing dissociation of the BRS-3 receptor ligand (125)I-Bantag-1, dose …
Efficacy and Safety of Low-Dose Iodine Plaque Brachytherapy for Juxtapapillary Choroidal Melanoma.
Oellers P, Mowery YM, Perez BA, Stinnett S, Mettu P, Vajzovic L, Light K, Steffey BA, Cai J, Dutton JJ, Buckley EG, Halperin EC, Marks LB, Kirsch DG, Mruthyunjaya P. Oellers P, et al. Am J Ophthalmol. 2018 Feb;186:32-40. doi: 10.1016/j.ajo.2017.11.008. Epub 2017 Dec 2. Am J Ophthalmol. 2018. PMID: 29199010
PURPOSE: To evaluate low- vs high-dose plaque brachytherapy for juxtapapillary choroidal melanoma. DESIGN: Retrospective interventional case series. ...STUDY POPULATION: Forty-seven patients with juxtapapillary choroidal melanoma. INTERVENTION: Iodine-125 pla …
PURPOSE: To evaluate low- vs high-dose plaque brachytherapy for juxtapapillary choroidal melanoma. DESIGN: Retrospective inter …
Feasibility of High-dose Iodine-131-metaiodobenzylguanidine Therapy for High-risk Neuroblastoma Preceding Myeloablative Chemotherapy and Hematopoietic Stem Cell Transplantation: a Study Protocol.
Araki R, Nishimura R, Inaki A, Wakabayashi H, Imai Y, Kuribayashi Y, Yoshimura K, Murayama T, Kinuya S. Araki R, et al. Asia Ocean J Nucl Med Biol. 2018 Spring;6(2):161-166. doi: 10.22038/aojnmb.2018.29845.1203. Asia Ocean J Nucl Med Biol. 2018. PMID: 29998150 Free PMC article.
The aim of this study is to evaluate the safety and efficacy of (131)I-MIBG radiotherapy combined with myeloablative high-dose chemotherapy and hematopoietic stem cell transplantation. ...Patients will receive 666 MBq/kg of (131)I-MIBG and after safety …
The aim of this study is to evaluate the safety and efficacy of (131)I-MIBG radiotherapy combined with myeloablative high-d …
Long-Term Outcome of Low- and High-Dose Radioiodine for Thyroid Remnant Ablation.
Liu S, Wu S, Ma C, Wang S, Chen S, Wang H, Feng F. Liu S, et al. Clin Endocrinol (Oxf). 2024 Dec;101(6):682-689. doi: 10.1111/cen.15134. Epub 2024 Sep 4. Clin Endocrinol (Oxf). 2024. PMID: 39233456 Clinical Trial.
Nine patients experienced recurrence in the low-dose group (8.7%), while eight patients experienced recurrence in the high-dose group (8.2%). The survival rates were 100% and 98.2% in the low- and high-dose groups, respectively. CONCLUSIONS: The …
Nine patients experienced recurrence in the low-dose group (8.7%), while eight patients experienced recurrence in the high- …
Trading off Iodine and Radiation Dose in Coronary Computed Tomography.
Fahrni G, Saliba T, Racine D, Gulizia M, Tzimas G, Pozzessere C, Rotzinger DC. Fahrni G, et al. J Cardiovasc Dev Dis. 2025 May 20;12(5):195. doi: 10.3390/jcdd12050195. J Cardiovasc Dev Dis. 2025. PMID: 40422966 Free PMC article. Review.
Advancements in CT technology, including iterative and deep-learning-based reconstruction, wide-area detectors, and dual-source systems, have helped mitigate early limitations, such as high radiation doses, motion artifacts, high iodine load, and non-diagnost …
Advancements in CT technology, including iterative and deep-learning-based reconstruction, wide-area detectors, and dual-source systems, hav …
An indirect high iodine ((131) I) effective dose used for thyroid ablation in patients with thyroid cancer. Is the method of measurement important?
Al-Shakhrah IA. Al-Shakhrah IA. J Appl Clin Med Phys. 2020 Jul;21(7):173-180. doi: 10.1002/acm2.12901. Epub 2020 Jun 23. J Appl Clin Med Phys. 2020. PMID: 32573916 Free PMC article.
BACKGROUND: Radiation effective dose to the red bone-marrow, a critical organ in the therapy of differentiated thyroid carcinoma (DTC) with radioiodine-131 ((131) I), cannot be measured directly. As radioiodine concentration is comparable in blood and most organs, and is b …
BACKGROUND: Radiation effective dose to the red bone-marrow, a critical organ in the therapy of differentiated thyroid carcinoma (DTC …
288 results